Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043022 | 0.93 | TLR9 (0.36) | LIPETLR9TLR8TLR7 | |
| SCHEMBL12059911 | 0.92 | LIPE (0.41) | LIPEENPP2EPHX2ADRB2P2RY14 | |
| SCHEMBL12043031 | 0.91 | ALDH1A1 (0.41) | TLR9TLR8TLR7 | |
| SCHEMBL12043042 | 0.91 | DRD2 (0.39) | TLR9TLR8TLR7 | |
| SCHEMBL12043030 | 0.90 | MCHR1 (0.41) | TLR9TLR8TLR7 | |
| SCHEMBL12059663 | 0.90 | LIPE (0.42) | LIPEENPP2EPHX2ADRB2P2RY14 | |
| SCHEMBL12060091 | 0.90 | CARM1 (0.42) | LIPEENPP2ADRB2 | |
| SCHEMBL12060092 | 0.90 | ENPP2 (0.46) | LIPEENPP2MC4R | |
| SCHEMBL12043047 | 0.89 | TLR9 (0.40) | TLR9TLR8TLR7 | |
| SCHEMBL12043052 | 0.89 | MEN1 (0.39) | TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | LIPE 1644/4885ENPP2 196/4885TLR9 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.